Want to see BYSI full AI Analyst Report?
BYSI Stock Chart & Stats
$1.66
-$0.09(-5.17%)
At close: 4:00 PM EST
$1.66
-$0.09(-5.17%)
Day’s Range― - ―
52-Week Range$1.16 - $2.44
Previous CloseN/A
Volume3.10K
Average Volume (3M)478.07K
Market Cap
$53.04M
Enterprise Value$61.59M
Total Cash (Recent Filing)$7.86M
Total Debt (Recent Filing)$246.00K
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Sep 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding41,119,820
10 Day Avg. Volume1,393,566
30 Day Avg. Volume478,066
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)-2.05
Price to Sales (P/S)0.00
P/FCF Ratio-3.28
Enterprise Value/Market Cap1.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.24K
Enterprise Value/Ebitda-7.68
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.98
Revenue Forecast (FY)$194.65M
Bulls Say, Bears Say
Bulls Say
Leadership UpgradeA targeted leadership refresh brings a CEO with capital-markets and regional partner experience and a CFO with listed-company finance background. Over the next 2–6 months this materially improves execution capacity for a Phase 3 program and strengthens investor and partner engagement.
Confirmatory Phase 3 ProgramHaving a confirmatory 442-patient Phase 3 trial in the clinic is a durable de-risking step for a biotech. Positive outcomes would enable regulatory filings, partnering and commercialization strategies; the trial itself provides tangible milestones to attract capital and partners long-term.
Improving Loss And Cash-burn TrendSustained reduction in annual net losses and a materially lower operating cash burn reflects tighter cost control and more disciplined spending. Over months this trend lengthens runway, lowers near-term financing pressure and improves the company's ability to negotiate non-dilutive partnerships or better financing terms.
Bears Say
Negative Shareholder EquityA materially negative equity base signals cumulative losses and asset depletion, constraining borrowing capacity and corporate flexibility. Structurally this weakens the balance sheet, can deter counterparties and complicate capital raises or M&A, raising long-term solvency and dilution risks.
Persistent Negative Cash FlowChronic negative operating and free cash flow creates an ongoing reliance on external financing. Over 2–6 months this elevates dilution and execution risk, since clinical programs and commercialization require capital; unsuccessful access to funding could delay trials or force unfavorable financing.
Pre-commercial, No RevenueWith no recurring product revenue, the company's fundamentals hinge on clinical success and partner deals. This leaves limited margin visibility and no internal cash generation buffer, increasing sensitivity to trial outcomes and external capital markets over the medium term.
Beyondspring News
BYSI FAQ
What was Beyondspring Inc’s price range in the past 12 months?
Beyondspring Inc lowest stock price was $1.16 and its highest was $2.44 in the past 12 months.
What is Beyondspring Inc’s market cap?
Beyondspring Inc’s market cap is $53.04M.
When is Beyondspring Inc’s upcoming earnings report date?
Beyondspring Inc’s upcoming earnings report date is Sep 04, 2026 which is in 46 days.
How were Beyondspring Inc’s earnings last quarter?
Beyondspring Inc released its earnings results on May 13, 2026. The company reported -$0.052 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.052.
Is Beyondspring Inc overvalued?
According to Wall Street analysts Beyondspring Inc’s price is currently Overvalued.
Does Beyondspring Inc pay dividends?
Beyondspring Inc does not currently pay dividends.
What is Beyondspring Inc’s EPS estimate?
Beyondspring Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beyondspring Inc have?
Beyondspring Inc has 41,119,820 shares outstanding.
What happened to Beyondspring Inc’s price movement after its last earnings report?
Beyondspring Inc reported an EPS of -$0.052 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.317%.
Which hedge fund is a major shareholder of Beyondspring Inc?
Currently, no hedge funds are holding shares in BYSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Beyondspring Inc
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
Technical Analysis
Plus Therapeutics
―
X4 Pharmaceuticals
―
ABVC BioPharma
―
Prelude Therapeutics
―
Gain Therapeutics
―
Ownership Overview
10.96% Insiders
2.19% Mutual Funds
9.38% Other Institutional Investors
75.69% Public Companies and
Individual Investors